Text Size

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

  • 2023
  • Clin Ther
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Neuroscience, University of Padua, Padua, Italy. Department of Ophthalmology, Tours University Hospital, Université François Rabelais, Hôpital Bretonneau, Tours, France. Department of Ophthalmology, Hospital Clinico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clinico San-Carlos (IdISSC), Madrid, Spain; Clínica Rementería, Madrid, Spain. Santen SAS, Évry-Courcouronnes, France. Department of Ophthalmology, Fondation A de Rothchild, Paris, France. University Hospital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; Rare Eye Disease Center (OPHTARA), Paris Cite University, Paris, France. Electronic address: dominique.bremond@aphp.fr.

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022